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Pernille B. Hansen, Christian B. Poulsen, Steen Walter, Niels Marcussen, Leanne L. Cribbs,
Ole Skøtt, Boye L. Jensen
Abstract—Calcium channel blockers are widely used for treatment of hypertension, because they decrease peripheral
vascular resistance through inhibition of voltage-gated calcium channels. Animal studies of renal vasculature have
shown expression of several types of calcium channels that are involved in kidney function. It was hypothesized that
human renal vascular excitation-contraction coupling involves different subtypes of channels. In human renal artery and
dissected intrarenal blood vessels from nephrectomies, PCR analysis showed expression of L-type (Cav 1.2), P/Q-type
(Cav 2.1), and T-type subtype (Cav 3.1 and Cav 3.2) voltage-gated calcium channels (Cavs), and quantitative PCR
showed highest expression of L-type channels in renal arteries and variable expression between patients of subtypes of
calcium channels in intrarenal vessels. Immunohistochemical labeling of kidney sections revealed signals for Cav 2.1
and Cav 3.1 associated with smooth muscle cells of preglomerular and postglomerular vessels. In human intrarenal
arteries, depolarization with potassium induced a contraction inhibited by the L-type antagonist nifedipine, EC50
1.2108 mol/L. The T-type antagonist mibefradil inhibited the potassium-induced constriction with large variations
between patients. Interestingly, the P/Q-type antagonist, -agatoxin IVA, inhibited significantly the contraction with
24% at 109 mol/L. In conclusion L-, P/Q, and T-type channels are expressed in human renal blood vessels, and L- and
P/Q-type channels are of functional importance for the depolarization-induced vasoconstriction. The contribution of
P/Q-type channels to contraction in the human vasculature is a novel mechanism for the regulation of renal blood flow
and suggests that clinical treatment with calcium blockers might affect vascular reactivity also through P/Q-type channel
inhibition. (Hypertension. 2011;58:464-470.) ● Online Data Supplement
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Calcium antagonists are widely used as pharmacologicaltreatment for arterial hypertension and act primarily
through vasodilation in the resistance vessels. Despite the
existence of several subtypes of voltage-gated calcium chan-
nels (Cav), the physiological importance of different subtypes
of calcium channels for vascular smooth muscle function in
humans is unknown.
The family of Cavs is divided into high-voltage activated
channels (including L- and P/Q-type Cavs), and low-voltage
activated channels, to which the T-type Cav belongs.1 Genes
encoding mRNAs for Cav 1-subunits have been cloned, and
the L-type channels include Cav 1.1 to 1.4, P/Q-type includes
Cav 2.1, and T-type channels include 3 different Cavs, 3.1 to
3.3. In animal studies, vascular smooth muscle cells from
renal preglomerular vessels express Cav 1.2, Cav 2.1, Cav 3.1,
and Cav 3.2.2–4 The expression of P/Q-type channels in aorta
and preglomerular and postglomerular smooth muscle cells
was surprising, because this channel is typically associated
with neurons and the most abundant calcium channel in the
brain5 with 2 splice variants, Cav 2.1a and b.6 Postglomerular
vessels from rats showed a regional heterogeneity in the
expression pattern of Cavs with L- (Cav 1.2) and T-type (Cav
3.1 and 3.2) subunits expressed in efferent arterioles from
juxtamedullary glomeruli, and only T-type-channels were
observed in mouse cortical efferent arterioles.3,7 In rodents,
excitation-contraction coupling in renal resistance vessels
involves several types of voltage-gated calcium channels, and
the activation mechanisms that induce vasoconstriction in
afferent and efferent arterioles in the renal cortex are differ-
ent. Depolarization and Cav activity are involved in the
pathway that leads to vasoconstriction in preglomerular
vasculature.8,9 In postglomerular efferent arterioles, calcium
influx pathways are not dependent on depolarization10 and are
resistant to L-type calcium channel antagonists11 and sensi-
tive to T-type antagonists.7,12 In vivo data confirm the
heterogeneity between afferent and efferent arterioles, and an
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important contribution from T-type channels has been sug-
gested for efferent arterioles.13–15
Several recent clinical studies have suggested that T-type
blockers have additional beneficial effects on renal function
and blood pressure compared with traditional L-type block-
ers.16–18 In a changeover study, benidipine (L- and T-type
antagonist) caused a larger reduction in blood pressure and
proteinuria compared with L-type treatment using amlodip-
ine.16 The observation of superior renoprotective effects with
a combined L- and T-type treatment is in agreement with
demonstration of a vasoconstrictor effect of T-type channels
on efferent arterioles in animal studies.
Because several types of Cav are involved in changes in
preglomerular and postglomerular vessel diameters in ro-
dents, inhibition of 1 or several Cavs will affect regulation of
renal blood flow, glomerular ultrafiltration pressure, and
medullary blood flow. These effects influence glomerular
filtration rate and salt and water homeostasis and thereby
blood pressure. Furthermore, the kidney vascular segments
are involved in several pathological conditions, such as
diabetes mellitus and hypertension. Despite this significant
clinical finding that indicates T-type channels in postglomer-
ular vessels in humans, there is no information available
regarding the expression patterns and functional significance
of Cav subtypes in the human renovascular bed. It is,
therefore, relevant to investigate the significance of Cav
subtypes in human renal blood vessels.
The purpose of the present study was to elucidate the
molecular expression pattern of Cavs and their functional
significance in human renal preglomerular arteries. Focus
was on L-, P/Q-, and T-type channels. Expression and
location of Cav were determined by PCR and immunostain-
ing. The functional importance was investigated by measure-
ment of force development in a myograph setting. Rings were
isolated from human intrarenal preglomerular arteries and
exposed to a standard depolarizing stimulus with and without
Cav blockers. In parallel, experiments were run on murine
intrarenal arteries for comparison.
Methods
Animals
The experimental protocol was approved by the Danish Animal
Experiments Inspectorate under the Danish Ministry of Justice, and
animal care followed the guidelines of the National Institutes of
Health for the Care and Use of Laboratory Animals. Male and female
mouse (C57BL/6) intrarenal arteries (segmental arteries) were iso-
lated by microdissection under a stereomicroscope for
functional studies.
Human Material
The use of human material was approved by the Danish Ethical
Committee and in agreement with declaration of Helsinki and Title
45, US Code of Federal Regulations, Part 46, Protection of Human
Subjects, Revised November 13, 2001, effective December 13, 2001.
Human renal blood vessels were taken from patients who underwent
nephrectomy. Only the part of the kidney consisting of normal tissue
was used. Human renal and intrarenal arteries (interlobar and arcuate
arteries) were isolated by microdissection.
PCR Analysis
RT-PCR and real-time PCR were performed on microdissected
mouse intrarenal arteries (segmental arteries) and human renal and
intrarenal arteries. For details please see the online Data Supplement
at http://hyper.ahajournals.org.
Immunohistochemistry
For Cav2.1 immunohistochemistry, human kidney sections were
incubated with primary antibody rabbit anti-Cav2.1 (Alomone ACC-
001). For Cav3.1 immunohistochemistry, sections of mouse and
human kidneys were incubated overnight using primary rabbit
anti-CaV3.1 antibody.19 For details please see the online
Data Supplement.
Isometric Force Measurements in Intrarenal
Arteries of Humans and Mice
Human and mouse intrarenal arteries were suspended in physiolog-
ical saline solution in a Halpern-Mulvany wire myograph, and
isometric force development was measured. Viability of the vascular
smooth muscle and endothelial cells was tested by demonstrating
contraction to phenylephrine (106 mol/L) and relaxation to acetyl-
choline (106 mol/L), respectively. For details please see the online
Data Supplement.
Protocols
In intrarenal arteries, the contraction induced by high potassium
solution at 70 mmol/L (EC75 human) or 50 mmol/L (EC75 mouse)
was tested in the presence of the -adrenoceptor antagonist phentol-
amine 105 mol/L to exclude potential involvement of nerve-
mediated responses. The effect of the L-type antagonist nifedipine
(109 to 106 mol/L) and the T-type antagonist mibefradil (109 to
105 mol/L) on high potassium solution-elicited constriction was
tested. The involvement of P/Q-type calcium channels was tested by
a concentration-response relationship using toxin -agatoxin IVA
(1010 to 108 mol/L, Alomine Laboratory, Jerusalem, Israel). For
details please see the online Data Supplement.
Statistical Analysis
Data are presented as meanSEM. Significance of changes was
calculated by 1-way ANOVA with Bonferroni. For details please see
the online Data Supplement.
Results
The study included 21 patients. The primary diagnoses were
either tumor or cysts. The median age was 63 years, and
median blood pressure was 134/77 mm Hg. For details please
see the online Data Supplement.
Expression of Calcium Channels in Human and
Mouse Renal Vasculature
To assess the expression profile of Cavs in renal blood vessels
from humans, PCR was applied on 9 patients. In human renal
arteries, expressions of mRNAs encoding Cav1.2, Cav2.1,
Cav3.1, and Cav3.2 were found (Figure 1A, results from 4
patients shown). Furthermore, mRNA from several types of
calcium channels was expressed within one patient’s renal
artery. In, for example, patient No. 181, Cav1.2, Cav2.1,
Cav3.1, and Cav3.2 were observed. When cDNA from human
intrarenal arteries was subjected to PCR, amplification prod-
ucts of the expected size were obtained for Cav1.2, Cav2.1,
Cav3.1, and Cav3.2, however, with some variation between
patients (Figure 1B). As for the renal arteries, intrarenal
arteries from the same patient also expressed several types of
calcium channels with some variability (Figure 1B). No
amplification was observed in negative controls with water
instead of cDNA or when reverse transcriptase was omitted in
the RT-PCR, thus confirming the mRNA origin of the
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amplification products. Positive controls were brain cDNAs,
and amplification yielded products of the expected size.
Using template from renal segmental arteries from mice
(Figure 1C), we observed amplification products of the
expected size for Cav1.2, Cav2.1a, Cav3.1, and Cav3.2.
We then examined the relative expression of the different
calcium channels compared with Cav1.2 in human renal
arteries and intrarenal arteries. In human renal arteries,
Cav1.2 was the most abundant in all patients with the
expression of Cav3.2Cav2.1 and Cav3.1 (Figure 2A). In
intrarenal vessels, Cav3.2 was largely expressed in all of the
patients and was even higher that the expression of Cav1.2 in
some patients (see Figure 2B). All of the patients expressed
all 4 of the channels. Mice intrarenal blood vessels expressed
all of the tested calcium channels, with Cav1.2 being the most
abundant, followed by Cav2.1a (Figure 2C).
Localization of Calcium Channels in Human
Renal Vasculature
Next, the distribution of Cav2.1 and Cav3.1 was examined in
human kidney sections. Labeling for Cav3.1 was associated
with the entire renal vasculature, including larger arteries
(Figure 3A), glomerular arterioles (Figure 3C), and vasa recta
(Figure 3D). Smooth muscle cells from all types of blood
vessels were stained. Furthermore, mice arteries and arteri-
oles also stained positive for Cav3.1 (Figure 3E), with no
labeling in the negative control (Figure 3B and 3F). Also,
labeling for Cav2.1 protein was observed in arteries and
arterioles of human sections (Figure 4). Interestingly, arteries
displayed immunopositive labeling for CaV2.1 in both
smooth muscle cells and endothelial cells (Figure 4A and
4B). Cortical glomerular arterioles were also positive for
CaV2.1 (Figure 4D). Figure 4E and 4F shows distinct staining
of medullary vasa recta. Omission of primary antibody
(negative control) yielded no staining (Figure 4C).
Isometric Force Measurements in Intrarenal
Arteries of Humans and Mice
The functional involvement of different types of calcium
channels was tested in isolated human intrarenal blood
vessels after depolarization. For details on vascular variability
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Figure 2. Real-time PCR analysis for voltage-gated calcium channel (Cav) in human and mice renal blood vessels. A, Percentage of
expression of CaV2.1, CaV3.1 and CaV3.2 compared with CaV1.2 in human renal arteries. Numbers refer to patient No. Data are means
for duplicate quantitative PCR determinationsSEM. B, Expression level of CaV2.1, CaV3.1, and CaV3.2 vs CaV1.2 in human intrarenal
arteries. Data are means for duplicate quantitative PCR determinationsSEM. C, Expression level of CaV2.1a and CaV2.1b, CaV3.1, and
CaV3.2 vs CaV1.2 in murine intrarenal arteries. Data are meanSEM (n4).
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Figure 1. PCR analysis for voltage-gated calcium channel (Cav) in human and mice renal blood vessels. A, RT-PCR amplification of
cDNA from 4 human renal arteries (R. artery; numbers refer to patient No.), CaV1.2, CaV2.1, CaV3.1, and CaV3.2. Positive control was
brain, and negative controls were brain-RT (omission of reverse transcriptase during reverse transcription), and H2O (water instead of
cDNA in the PCR). B, As A but using cDNA from human intrarenal arteries as template. C, Expression of CaV1.2, CaV2.1a, CaV3.1, and
CaV3.2 in murine intrarenal arteries (n4). Positive control was whole kidney and negative controls were kidney-RT, omission of reverse
transcriptase, and H2O.
466 Hypertension September 2011
 by guest on January 15, 2017
http://hyper.ahajournals.org/
D
ow
nloaded from
 
between patients, please see the online Data Supplement.
Potassium concentration-dependently contracted human
blood vessels with an EC75 of 70 mmol/L, and administration
of the L-type antagonist nifedipine concentration-
dependently inhibited contraction (EC50 of 1.2108 mol/L),
with a first significant inhibition (from 100.0% to 5.79.6%)
at 107 mol/L (Figure 5A). Full inhibition was obtained in all
of the patients at 106 mol/L of nifedipine. In mice, nifedi-
pine also concentration-dependently inhibited the potassium-
induced contraction with a significant inhibition at 108
mol/L (Figure 5B).
Next we examined whether the T-type Cavs are involved in
depolarization-induced contraction. Mibefradil had a very
variable effect on blood vessels from different patients with a
significant inhibition of the potassium-induced contraction at
105 mmol/L to 40.66.0% contraction with an EC50 of
6.8107 mol/L (Figure 5C). In mice, a less variable
response was observed, and the first significant inhibition was
obtained at a concentration of 106 mmol/L (Figure 5D).
The functional effect of the P/Q-type channels was tested
by application of the antagonist -agatoxin IVA. The antag-
onist dose-dependently inhibited the contraction with signif-
icant inhibition from 100.0% to 75.82.9% at 109 mmol/L
(Figure 5E). -Agatoxin IVA had no significant effect in
mice intrarenal vessels (Figure 5F).
Discussion
The present study establishes by combined molecular identi-
fication, immunohistochemical localization, and in vitro
pharmacological characterization that L-, P/Q-, and T-type
calcium channels are expressed, and L- and P/Q-type chan-
nels are of functional importance in human renal preglomer-
ular arteries. Also, postglomerular vessels express P/Q- and
T-type channels, and particularly P/Q-type channels were
associated with the endothelium in postglomerular vasa recta.
Similar results have been obtained in vasculature of ro-
dents.2–4 The involvement of different types of calcium
channels in human renal vascular contractility has been
unclear, but the present study shows for the first time that
depolarization consistently constricts the blood vessels not
only through an L-type channel–dependent activation but
also with the involvement of the P/Q type. No significant
effect of T-type blockade on contraction was observed.
Immunohistochemical localization and mRNA detection
corroborate novel evidence for the coexistence of P/Q-type,
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Figure 3. Immunohistochemistry for voltage-gated calcium
channel (Cav) 3.1. Human kidney sections showing a large
intrarenal artery (IR; A), a glomerular arteriole (GA; C), and vasa
recta (VR; D) labeled with anti-CaV3.1 antibody. CaV3.1 labeling
of mouse intrarenal artery (IR; E). Omission of primary antibody
served as control (B and F).
A B
EC
SMC
C D
GA
VSMC
E F
EC
VR VR
h-IR Artery
Negative Control
h-IR Artery
h-Cortical Arteriole
h-Vasa Recta
h-IR Artery
h-Vasa Recta
Figure 4. Immunohistochemical labeling of human kidney sec-
tions for voltage-gated calcium channel (Cav) 2.1. Human kidney
sections showing a large intrarenal artery with smooth muscle
cells and endothelial cells (EC; A), intrarenal artery with smooth
muscle cells (SMC) and endothelial cells (B), glomerular arteriole
(GA; D) and postglomerular outer medullary vasa recta bundles
(VR) in cross-section (E) and longitudinal section (F), labeled
with anti-CaV2.1 antibody. Omission of primary antibody served
as negative control (C).
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T-type, and L-type Cavs in identical vascular segments of the
human kidney in agreement with rodent data.4,8 The dissec-
tion technique allowed us to isolate mRNA from intrarenal
arteries, and the expression level of the channels was variable
between patients. However, all of the patients expressed
several types of calcium channels. The variability could be
attributed to individual genetic or (patho)physiological dif-
ferences, but also the different primary diseases and variable
pharmacological regimens could be important. Hypertensive
rats have increased expression of L-type channels in vascular
smooth muscle cells, and increased blood pressure and
membrane depolarization promote channel expression at the
cell membrane.20 Whether this is true for humans need to be
investigated.
Immunohistochemistry data show that the channels are
expressed in vascular smooth muscle cells and suggest an
expression of P/Q-type channels in endothelial cells in both
large arteries and vasa recta. In a recent study of calcium
current in rat vasa recta pericytes, P/Q-type antagonist had no
effect on calcium currents,21 in contrast to rat preglomerular
myocytes.4 However, endothelial cells were not investigated.
Cavs of the Cav3.2 and Cav3.1 types have been reported
previously in endothelial cells in rats,22,23 albeit with unclear
function. The antibody specific for the T-type subunit Cav3.2
did not apply to human tissue, and we did not observe a
Cav3.1 labeling of human renal endothelial cells.
In agreement with the molecular data, functional data from
the present study provide new evidence for the involvement
of several types of channels in the excitation-contraction
mechanism in human renal vasculature. Depolarization led to
contraction that was sensitive to the L-type antagonist nifed-
ipine in all of the tested patients, which confirms the exquisite
voltage dependence of preglomerular contraction known
from many species. Also, the EC50 observed in the present
study (EC50 of 1.2108 mol/L) is in agreement with the
reported human EC50 for L-type channels (EC50 of 1 to
10108 mol/L). Surprisingly, also P/Q-type channels con-
tributed to the potassium-induced contraction, because the
specific P/Q-type antagonist -agatoxin IVA inhibited the
contraction by 24%. -Agatoxin IVA is a selective P/Q-
type antagonist that blocks P-type channels at concentrations
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Figure 5. Depolarization-induced contraction of human and mouse intrarenal arteries. A, Effect of increasing concentrations of nifedi-
pine (109 to 106 mol/L) on potassium-induced contraction in human intrarenal (IR) arteries mounted in a myograph. Data shown are
individual patients including means (n6). Numbers refer to patient No. B, Dose-response effect of nifedipine in murine intrarenal (IR)
arteries on potassium induced contraction. Data are meanSEM (n6). C, Effect of T-type voltage-gated calcium channel (Cav) inhibi-
tion by mibefradil on potassium-induced contraction in human intrarenal blood vessels. The response was variable between individual
patients (numbers refer to patient No.). Data shown are individual patients including means (n7). D, Dose-response effect of mibefradil
in murine intrarenal arteries on potassium-induced contraction. Data are meanSEM (n6). E, Effect of increasing concentrations of
-agatoxin IVA (1010 to 108 mol/L) on potassium-induced contraction in human intrarenal arteries. Data shown are individual patients
including means (n6). F, Dose-response effect of -agatoxin IVA in murine intrarenal arteries on potassium-induced contraction. Data
are meanSEM (n6). *P0.05 vs potassium alone.
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10 nmol/L, whereas the Q channels are inhibited at higher
concentrations,24 and the observed effect at low concentra-
tions of -agatoxin IVA in the present study is, therefore,
probably attributed to a P-type current. This effect indicates a
new player in the contraction mechanism in human renal
arteries. In agreement, Cav2.1-mediated currents have been
observed in human umbilical arteries and rat preglomerular
myocytes.2,25 The biophysical properties vary between cal-
cium currents. Compared with L-type currents, P/Q-type
Ca2	 currents are slower, have a Ca2	-independent rate of
inactivation, and have inhibitory modulation by G proteins.
The latter feature is involved in hormonal regulation of
channel properties26; thus, the presence of P/Q-type currents
in the human vasculature could give rise to novel mechanisms
for hormonal influence on human intrarenal vascular reactiv-
ity. In rodents, P/Q-type calcium channels contribute signif-
icantly to the increase in intracellular [Ca2	] and contraction
after depolarization of renal vasculature.4 Mice deficient in
P/Q-type Cav display a phenotype with pronounced neuro-
logical deficits, but abnormalities of cardiovascular function
were not investigated.27 In humans, mutations in the gene
encoding the CaV2.1 subunit are associated with episodic
ataxia type 2, familial hemiplegic migraine, and spinocere-
bellar ataxia type 6.28,29 Whether mutations in the CaV2.1
subunit gene are involved in the pathogenesis of renal and
vascular disorders is unknown.
The T-type blocker mibefradil selectively inhibits T-type
currents at low concentrations, with an EC50 of 10 nmol/
L.30,31 In the present study, mibefradil blocked K	-induced
contraction at 109 mol/L in some patients, whereas in others
the contraction was not affected until 106 mol/L, a concen-
tration also inhibiting L-type channels. Our data show a large
variation between patients questioning whether T-type chan-
nels play a role for contraction of larger renal vasculature, and
with a mean EC50 of 6.8107 mol/L, no significant T-type
channel effect was observed. In agreement, T-type channels
have been shown to have their dominant effects in smaller
human and rat arterioles compared with larger arteries.32 Also
in rodents, T-type channels are most important for the
contraction of smaller blood vessels,33 suggesting that T-type
channels might also be of greater significance in human renal
arterioles compared with arteries.
Calcium blockers are widely used in conditions such as
hypertension34,35 because they possess the ability to decrease
peripheral vascular resistance, affect renal tubules leading to
natriuresis, and affect cardiac function. The antagonists differ
in their selectivity toward L-, T-, and P/Q-type calcium
channels.36 L-type calcium channel blockers, such as the
dihydropyridines verapamil and diltiazem, have been re-
ported to significantly inhibit T-type and P-type calcium
currents when used in concentrations that are not maximal for
the L-type blockade.36,37 Amlodipine inhibits L- and P/Q-type
calcium channels equally well in oocytes, whereas nifedipine
is selective toward L-type channels. Such differences may
contribute to in vivo differences of the calcium channel
blockers in vascular beds. The present demonstration of
functional P/Q-type Cav in the human renal vasculature
therefore suggests that certain conventional calcium channel
blockers also exert effects on P-type Cav.
Our evidence for T-type channels in human renal blood
vessels is in agreement with the notion that T-type blockers
have specific and beneficial intrarenal effects compared with
L-type blockers.16–18 In a crossover study, benidipine (L- and
T-type antagonist) caused a larger reduction in blood pressure
and proteinuria compared with L-type treatment using amlo-
dipine,16 and benidipine favorably affects renal function in
patients with essential hypertension compared with amlodip-
ine.18 These studies suggest a clinical benefit of benidipine
over amlodipine as an antihypertensive drug because of a
renoprotective effect. The observation of superior renopro-
tective effects with a combined L- and T-type treatment is in
agreement with the previous demonstration of a differential
expression of calcium channels in rodent kidney with a
vasoconstrictor effect of T-type channels on efferent arteri-
oles.3,8 This information is not yet available from the human
kidneys for technical reasons. A study on human glomerular
arterioles would elucidate this issue to be of great interest,
because these vascular resistance vessels determine renal
blood flow rate and glomerular filtration rate and affect blood
pressure.
Perspectives
In conclusion, L-, P/Q-, and T-type Cavs are present in human
renal blood vessels, and L- and P/Q-type channels are of
functional importance for the depolarization-induced vaso-
constriction. These novel observations are relevant for the
understanding of regulation of human renal blood flow and
glomerular filtration rate and should be considered when
choosing calcium blockers for clinical treatment. The func-
tional importance of P/Q-type channels in the human vascu-
lature could give rise to novel mechanisms for the regulation
of renal blood flow and suggests that clinical treatment with
calcium blockers might affect vascular reactivity through
P/Q-type channel inhibition.
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Expanded materials and methods 
 
Animals 
Male and female mice (C57BL/6) had free access to rodent chow (Altromin, Lage, Germany) and 
tap water. Mouse intra-renal arteries (segmental arteries) were isolated by microdissection under 
stereomicroscope for functional studies.  
 
Human Material 
Human renal blood vessels were taken from patients, who underwent nephrectomy for renal cancer 
or cysts. Only the part of the kidney consisting of normal tissue was used. All patients gave their 
informed written consent to participate in the study. Kidneys were extirpated and immediately 
transported to the Institute of Pathology.  Human renal and intra-renal arteries (interlobar and 
arcuate arteries) were isolated by microdissection under stereomicroscope within one hour of 
receival of the material.  
 
PCR-analysis: 
Reverse Transcription PCR and real-time PCR was performed : RNA was isolated from 
microdissected mouse intra-renal arteries (segmental arteries) and human renal and intra-renal 
arteries by TRIzol reagent from Invitrogen (Carlsbad, CA, USA) and reverse transcribed using 
Superscript and oligo (dT). PCR consisted of 35 cycles and each cycle included incubation at 95ºC 
for 20 seconds, 60ºC for 20 seconds and 72ºC for 20 seconds. Specific primers were used for each 
receptor subtype. 
Real-time PCR: Quantitative three-step real-time PCR was performed on a Mx3000 real time PCR 
instrument (Stratagene) using 2X IQ SYBR Green Supermix (BIO-RAD) according to the 
instructions from the manufacturer. All measurements were performed in duplicate. Real-time PCR 
consisted of 40 cycles and each cycle included incubation at 95ºC for 20 seconds, 60ºC for 20 
seconds and 72ºC for 20 seconds. Specific primers were used for each receptor subtype. 
Mouse primers Cav1.2(Genbank NM009781 sense 5’-TGC CTA CGG ACT TCT CTT CC-3’ and 
antisense 5’-GCT CCT TTC CCT CCT AGA GC-3’ covering 150bp), Cav2.1(Genbank NM 007578 
sense 5’-GCC CTT CGA GTG TTC AAC-3’ and antisense(Cav2.1a, P-type channels)2  5’-CTC 
AGG TTG ATG AAG TTA TTC C-3’ covering 185bp, antisense(Cav2.1b, Q-type channels) 5’-
CAG GTT GAT GAA GTT ATT CGG-3’ covering 189bp), Cav3.1(Genbank NM 009783 sense 5’-
GAA CGT GAG GCC AAG AGT-3’ and antisense 5’-GCT CGT AAG CGT TCC CCT-3 covering 
221bp), Cav3.2(Genbank NM 021415 sense 5’-GCT CTC CCC CGT CTA CTT CG -3’ antisense 
5’-AGA TAC TTT GCG CAC GAC CAG G-3’ covering 247bp). GAPDH, sense 5’-TGA TGG 
CAT GGA CTG TGG-3’ antisense 5’-CAG CAA TGC ATC CTG CAC-3’ covering 104bp. 
Human primers: Cav1.2(Genbank NM 199460 sense 5’- GCA ACG GCT GGA ACC TAC TA-3’ 
and antisense 5’-CGA TGA TGG CGT AGA TGA TG-3’ covering 282), Cav2.1(Genbank NM 
001127222 sense 5’- CAA CCA CAC CGT CGT ACA AG-3’  and antisense 5’-AAA GTA GCG 
CAG GTT CAG GA-3’ covering 202bp), Cav3.1(Genbank NM 018896 sense 5’-CTT CGA TGG 
TGT CAT TGT GG-3’ and antisense 5’-TAA GCA GCA TGC AGA AGG TG-3’ covering 227bp), 
Cav3.2(Genbank NM 021098 sense 5’- ATC ATG CTC AAC TGC GTG AC-3’ and antisense 5’-
TTG TGT CCG TCC AAC GAG TA-3’ covering 248bp). GAPDH, sense 5’- CGA GAT CCC TCC 
AAA ATC AA-3’ antisense 5’- GTC TTC TGG GTG GCA GTG AT-3’ covering 323bp. 
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Negative controls included water and RNA where no reverse transcriptase was added to the reaction 
(-RT). Positive control was whole kidney tissue (mouse) and human brain for the human part of the 
study (BD – Diagnostic Systems, USA). The efficiency of the all primers used was between 95-
100%.   
Immunohistochemistry 
For Cav2.1 immunohistochemistry, human kidneys were embedded in paraffin and cut in 4 µm 
slices. Then permeabilized using ethanol in decreasing concentrations (99% ->70%) followed by 
3% goat serum and incubation with primary antibody rabbit anti-Cav2.1 diluted 1:50 (Alomone 
ACC-001) over night. For Cav3.1 immunohistochemistry, paraffin embedded sections of mouse and 
human kidneys were treated with 0.2% triton X followed by 0.5 % hydrogen peroxide for 5 minutes 
and 3% bovine serum albumin. Next the sections were incubated overnight using primary rabbit 
anti-CaV3.1 antibody 19 diluted 1:500. Secondary antibody goat anti-rabbit IgG, horseradish 
peroxidase labeled (DAKO) or Alexa 568 conjugated goat anti-rabbit (Molecular Probes) diluted 
1:1000 were applied. Horseradish peroxidase labeled sections were stained with diaminobenzidine 
(DAB+ substrate-chromogen system, DAKO) and counter stained with hematoxylin. 
 
Isometric force measurements in intra-renal arteries of human and mice  
Human intra-renal arteries consisting of interlobar and arcuate arteries and renal arteries were 
removed under stereomicroscope and stored in the following solution, in mmol/L: NaCl 103, KCl 
5.4, NaHCO3 4.0, NaH2PO4 1.5, MgSO4 0.8, glucose 5.1, Na-pyruvate 0.9, Na-isethionic acid 30, 
HEPES 5.6 and in ml/L: MEM vitamin solution 10 (Sigma M6895), MEM essential amino acid 
solution 20 (Sigma M5550), and MEM nonessential amino acid solution 10 (Sigma M7145) at 4⁰C 
until further use. Mice were killed by cervical dislocation and the kidneys were placed in ice cold 
physiological salt solution (PSS), in mmol/L: NaCl 115, NaHCO3 25, MgSO4 1.2, K2HPO4 2.5, 
CaCl2 1.3, glucose 5.5, and HEPES 10 equilibrated with 5 % CO2 in air at pH 7.4. Human and 
mouse intra-renal arteries were suspended in PSS in a Halpern-Mulvany wire myograph (model 
610, Danish Myo Technology A/S, Aarhus, Denmark) and isometric force development was 
measured (PowerLab, ADInstruments, Colorado Springs, CO, USA). Two rings per artery were 
incubated at 37 °C in PSS. Then, the rings were normalized according the manufactorers protocol 
and allowed to equilibrate for 30 minutes. Viability of the vascular smooth muscle and endothelial 
cells was tested by demonstrating contraction to phenylephrine (10-6 mol/L) and relaxation to 
acetylcholine (10-6 mol/L), respectively. This was repeated by the end of the experiment.  Blood 
vessels developing a contraction larger than 2 mN in response to phenylephrine were included in 
the study. 
Protocols: human arteries. In intra-renal arteries the contraction induced by high potassium 
solution (HPS) 70 mM (EC75) was tested in the presence of the alpha-adrenoceptor antagonist 
phentolamin (PHE) 10-5mol/L to exclude potential involvement of nerve mediated responses. The 
effect of the L-type antagonist nifedipine (10-9-10-6 mol/L, Sigma-Aldrich) on HPS-elicited 
constriction was tested. Each concentration of nifedipine was applied for 5 minutes in the presence 
of PHE followed by 5 minute HPS administration; this was repeated for each concentration. 
Furthermore, concentration-response curves were obtained for the T-type antagonist mibefradil 
(Sigma-Aldrich) in the concentration range 10-9 to 10-5 mol/L. The involvement of P/Q-type 
calcium channels was tested by a concentration- response relationship using toxin ω-agatoxin IVA 
(10-10-10-8 mol/L, Alomine Lab. Jerusalem, Israel).   
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Protocols: mouse arteries.Concentration-response curves were obtained for nifedipine, mibefradil 
ω-agatoxin IVA as described for human material using 50 mmol/L potassium (EC75) instead of 70 
mmol/L.  
Statistical Analysis 
Data are presented as means ± SEM; n represents the number of experiments with different mice or 
humans. Myograph data were normalized to consecutive applications of high potassium as several 
administrations of potassium led to increased potassium induced responses. Significance of changes 
was calculated by one-way analysis of variance (ANOVA) with Bonferroni reduction for multiple 
comparisons. P<0.05 was considered significant. 
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Tables and supporting information 
 
The study included 21 patients (15 males and 6 females).  The primary diagnoses were either tumor 
or cysts (Table S1). The median age was 63 (range 28-81 years) and median blood pressure was 134 
/77 mmHg (range 146 ± 4/ 81 ± 1 mmHg (Table S1). None of the patients were treated with 
calcium blockers before donation of kidney material.  
 
Table S1. Characteristics of the patient cohort that was examined. BP: Systolic/diastolic blood 
pressure before surgery. Renal cell carcinomas (RCC) 
 
Pt. No. Gender Age years BP mmHg Pathological diagnosis-WHO criteria  
153 F 63 133/83 RCC  
154 M 80 185/99 RCC  
155 F 65 155/66 RCC  
156 F 54 160/95 RCC  
157 M 71 147/75 n/a  
158 M 44 120/80 RCC  
159 F 76 168/81 Papillary-RCC  
161 M 52 151/106 RCC  
165 M 45 136/91 Hydronephrose  
166 M 62 152/109 RCC  
168  M 72 n/a n/a  
172 F 41 139/69 Hydronephrose  
173 M 81 174/77 RCC  
174 
181 
193 
194 
197 
248 
250 
999 
M 
M 
M 
M 
M 
M 
M 
F 
72 
81 
28 
69 
69 
82 
62 
58 
134/67 
171/73 
131/77 
149/79 
137/77 
126/72 
134/83 
123/71 
RCC 
Papillary-RCC 
RCC 
RCC 
RCC 
RCC 
RCC 
RCC  
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